Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. More Details
Solid track record average dividend payer.
Share Price & News
How has Abbott Laboratories's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ABT is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 2% a week.
Volatility Over Time: ABT's weekly volatility (2%) has been stable over the past year.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: ABT underperformed the US Medical Equipment industry which returned 34.6% over the past year.
Return vs Market: ABT underperformed the US Market which returned 33.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Abbott Laboratories's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StI Ran A Stock Scan For Earnings Growth And Abbott Laboratories (NYSE:ABT) Passed With Ease
3 weeks ago | Simply Wall StAbbott Laboratories' (NYSE:ABT) investors will be pleased with their splendid 224% return over the last five years
1 month ago | Simply Wall StCalculating The Fair Value Of Abbott Laboratories (NYSE:ABT)
Is Abbott Laboratories undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ABT ($126.79) is trading below our estimate of fair value ($128.71)
Significantly Below Fair Value: ABT is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: ABT is good value based on its PE Ratio (35.4x) compared to the US Medical Equipment industry average (53.4x).
PE vs Market: ABT is poor value based on its PE Ratio (35.4x) compared to the US market (17.8x).
Price to Earnings Growth Ratio
PEG Ratio: ABT is poor value based on its PEG Ratio (3.1x)
Price to Book Ratio
PB vs Industry: ABT is overvalued based on its PB Ratio (6.7x) compared to the US Medical Equipment industry average (4.8x).
How is Abbott Laboratories forecast to perform in the next 1 to 3 years based on estimates from 23 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ABT's forecast earnings growth (11.3% per year) is above the savings rate (2%).
Earnings vs Market: ABT's earnings (11.3% per year) are forecast to grow slower than the US market (14.8% per year).
High Growth Earnings: ABT's earnings are forecast to grow, but not significantly.
Revenue vs Market: ABT's revenue (4.4% per year) is forecast to grow slower than the US market (9.8% per year).
High Growth Revenue: ABT's revenue (4.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ABT's Return on Equity is forecast to be high in 3 years time (23.8%)
How has Abbott Laboratories performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ABT has high quality earnings.
Growing Profit Margin: ABT's current net profit margins (15.8%) are higher than last year (9.8%).
Past Earnings Growth Analysis
Earnings Trend: ABT's earnings have grown significantly by 36.8% per year over the past 5 years.
Accelerating Growth: ABT's earnings growth over the past year (106.4%) exceeds its 5-year average (36.8% per year).
Earnings vs Industry: ABT earnings growth over the past year (106.4%) exceeded the Medical Equipment industry 40.5%.
Return on Equity
High ROE: ABT's Return on Equity (18.7%) is considered low.
How is Abbott Laboratories's financial position?
Financial Position Analysis
Short Term Liabilities: ABT's short term assets ($22.6B) exceed its short term liabilities ($12.6B).
Long Term Liabilities: ABT's short term assets ($22.6B) do not cover its long term liabilities ($26.6B).
Debt to Equity History and Analysis
Debt Level: ABT's debt to equity ratio (54.4%) is considered high.
Reducing Debt: ABT's debt to equity ratio has increased from 42.8% to 54.4% over the past 5 years.
Debt Coverage: ABT's debt is well covered by operating cash flow (57.5%).
Interest Coverage: ABT's interest payments on its debt are well covered by EBIT (16.3x coverage).
What is Abbott Laboratories's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: ABT's dividend (1.42%) is higher than the bottom 25% of dividend payers in the US market (1.33%).
High Dividend: ABT's dividend (1.42%) is low compared to the top 25% of dividend payers in the US market (3.6%).
Stability and Growth of Payments
Stable Dividend: ABT's dividend payments have been volatile in the past 10 years.
Growing Dividend: ABT's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (47.9%), ABT's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: ABT's dividends in 3 years are forecast to be well covered by earnings (36.5% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Robert Ford (47 yo)
Mr. Robert B. Ford has been the Chief Executive Officer and Director of Abbott Laboratories since March 31, 2020. He has been President at Abbott Laboratories since October 15, 2018 and served as its Execu...
CEO Compensation Analysis
Compensation vs Market: Robert's total compensation ($USD20.45M) is above average for companies of similar size in the US market ($USD11.33M).
Compensation vs Earnings: Robert's compensation has increased by more than 20% in the past year.
Experienced Management: ABT's management team is considered experienced (2.1 years average tenure).
Experienced Board: ABT's board of directors are considered experienced (9.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Abbott Laboratories's company bio, employee growth, exchange listings and data sources
- Name: Abbott Laboratories
- Ticker: ABT
- Exchange: NYSE
- Founded: 1888
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$224.776b
- Shares outstanding: 1.77b
- Website: https://www.abbott.com
Number of Employees
- Abbott Laboratories
- 100 Abbott Park Road
- Abbott Park
- North Chicago
- United States
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/19 22:04|
|End of Day Share Price||2021/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.